Type 1 Diabetes | CHOP Research Institute

Type 1 Diabetes

Published on
Jan 11, 2023
Diversity Fellow Alfonso Floyd, PhD, studies the impact of risk and resilience on the mental health of minority youth with type 1 diabetes.
Published on
Jun 2, 2022
CHOP and Penn researchers discussed the latest findings about the mechanisms of immunity at the CHOP Research Institute 2022 Scientific Symposium.
Published on
Sep 3, 2021
This week’s In the News highlights two new studies, a new grant, the new director of the Cystic Fibrosis Center, and a physician’s new role.

PRONTO-PEDS will test if a ultra-fast insulin product given before or immediately after meals improves glycemic control in children and teens with type 1 diabetes.

This is a study that investigates whether an IV medication (teplizumab) will slow or halt the progression of type 1 diabetes in children and adolescents (ages 8 - 17 years).

Dr. Weber is a clinical researcher focused on improving bone health in children. He is currently focused on investigating the effects of effects of type 1 diabetes and Duchenne muscular dystrophy on the skeleton. 

weberd [at] chop.edu
Published on
May 28, 2020
Michael Silverman, MD, PhD, is pursuing research to learn how gut bacteria may help signal genes to prevent type 1 diabetes.

The Silverman Lab investigates early-life modifiable factors influencing the development and function of the immune system and harnesses these factors to prevent autoimmune diabetes (T1D). The lab discovered that the major histocompatibility complex class II E molecule prevents T1D by shaping the intestinal microbiota early in life.

Dr. Monos is an internationally recognized expert on histocompatibility (HLA) molecules. His work covers a wide spectrum of HLA-related issues that pertain to both the molecular (structure/function) aspects of HLAs, as well as the genetics of the major histocompatibility complex, that includes the genes encoding the HLA molecules.

monosd [at] chop.edu
lipman [at] chop.edu